Sublingual immunotherapy for 4 years increased the number of Foxp3+ Treg cells, which correlated with clinical effects
Objective At least 3 years of sublingual immunotherapy (SLIT) is required to achieve long-term clinical tolerance for allergens. However, immunological changes with more than 3 years of SLIT have not yet been elucidated in detail. The present study investigated whether the numbers of regulatory T (T...
Gespeichert in:
| Veröffentlicht in: | Inflammation research 2021-05, Vol.70 (5), p.581-589 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 589 |
|---|---|
| container_issue | 5 |
| container_start_page | 581 |
| container_title | Inflammation research |
| container_volume | 70 |
| creator | Terada, Tetsuya Matsuda, Masaya Inaba, Miki Hamaguchi, Junpei Takemoto, Naoki Kikuoka, Yusuke Inaka, Yuko Sakae, Harumi Hashimoto, Kennosuke Shimora, Hayato Kitatani, Kazuyuki Kawata, Ryo Nabe, Takeshi |
| description | Objective
At least 3 years of sublingual immunotherapy (SLIT) is required to achieve long-term clinical tolerance for allergens. However, immunological changes with more than 3 years of SLIT have not yet been elucidated in detail. The present study investigated whether the numbers of regulatory T (Treg) cells and regulatory B (Breg) cells increased with 4 years of SLIT and if these increases correlated with clinical effects for pollinosis.
Methods
Seven Japanese cedar pollinosis patients received SLIT in 2014 or 2015 and continued treatment until May 2019. In May 2017 and May 2019, peripheral blood mononuclear cells (PBMCs) were collected from the patients, and analyzed by flow cytometer.
Results
(1) The visual analogue scale (VAS) was significantly higher in 2019 than in 2017. (2) The percentages of Foxp3
+
Treg cells, type 1 regulatory T (Tr1) cells, and Breg cells in PBMCs were significantly higher in 2019 than in 2017. (3) The percentage of Foxp3
+
Treg cells in PBMCs positively correlated with VAS, whereas those of Tr1 cells and Breg cells did not.
Conclusions
These results suggest that 4 years of SLIT is needed to achieve sustained increases in Foxp3
+
Treg cells, which are closely associated with the efficacy of SLIT. |
| doi_str_mv | 10.1007/s00011-021-01460-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2511244463</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2511244463</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-8297c16333fc706570c6f1979461fa58cb878555b2de62c5394e00909c3334613</originalsourceid><addsrcrecordid>eNp9kc-KFDEQxoMo7jr6Ah4k4EXQ1sqf7qSPy-KqsODBFbyFdKYy00t3Z0y6GedtfBafzBpnVfDgISSV-tX3FXyMPRXwWgCYNwUAhKhA0hG6gUrdY-dCS6hasF_u0xukqpRVcMYelXJLuJVWPmRnij6NVvac7T8t3dBPm8UPvB_HZUrzFrPfHXhMmesf3w_oc-H9FDL6gmtObT4tY4eZp8iv0redeslvMm54wGEor_h-24ctDylnHPxME_t-pppM-kAmGCOGuTxmD6IfCj65u1fs89Xbm8v31fXHdx8uL66roEw9V1a2JohGKRWDgaY2EJooWtPqRkRf29BZY-u67uQaGxlq1WoEaKENNEKMWrEXJ91dTl8XLLMb-3Lc1E-YluJkLYTUWpPFij3_B71NS55oO6Kk1K0hI6LkiQo5lZIxul3uR58PToA7xuJOsTiKxf2KxR2ln91JL92I6z8jv3MgQJ2AQq1pg_mv939kfwJeGJdC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2522497555</pqid></control><display><type>article</type><title>Sublingual immunotherapy for 4 years increased the number of Foxp3+ Treg cells, which correlated with clinical effects</title><source>SpringerLink</source><creator>Terada, Tetsuya ; Matsuda, Masaya ; Inaba, Miki ; Hamaguchi, Junpei ; Takemoto, Naoki ; Kikuoka, Yusuke ; Inaka, Yuko ; Sakae, Harumi ; Hashimoto, Kennosuke ; Shimora, Hayato ; Kitatani, Kazuyuki ; Kawata, Ryo ; Nabe, Takeshi</creator><creatorcontrib>Terada, Tetsuya ; Matsuda, Masaya ; Inaba, Miki ; Hamaguchi, Junpei ; Takemoto, Naoki ; Kikuoka, Yusuke ; Inaka, Yuko ; Sakae, Harumi ; Hashimoto, Kennosuke ; Shimora, Hayato ; Kitatani, Kazuyuki ; Kawata, Ryo ; Nabe, Takeshi</creatorcontrib><description>Objective
At least 3 years of sublingual immunotherapy (SLIT) is required to achieve long-term clinical tolerance for allergens. However, immunological changes with more than 3 years of SLIT have not yet been elucidated in detail. The present study investigated whether the numbers of regulatory T (Treg) cells and regulatory B (Breg) cells increased with 4 years of SLIT and if these increases correlated with clinical effects for pollinosis.
Methods
Seven Japanese cedar pollinosis patients received SLIT in 2014 or 2015 and continued treatment until May 2019. In May 2017 and May 2019, peripheral blood mononuclear cells (PBMCs) were collected from the patients, and analyzed by flow cytometer.
Results
(1) The visual analogue scale (VAS) was significantly higher in 2019 than in 2017. (2) The percentages of Foxp3
+
Treg cells, type 1 regulatory T (Tr1) cells, and Breg cells in PBMCs were significantly higher in 2019 than in 2017. (3) The percentage of Foxp3
+
Treg cells in PBMCs positively correlated with VAS, whereas those of Tr1 cells and Breg cells did not.
Conclusions
These results suggest that 4 years of SLIT is needed to achieve sustained increases in Foxp3
+
Treg cells, which are closely associated with the efficacy of SLIT.</description><identifier>ISSN: 1023-3830</identifier><identifier>EISSN: 1420-908X</identifier><identifier>DOI: 10.1007/s00011-021-01460-3</identifier><identifier>PMID: 33837438</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Allergens ; Allergology ; Biomedical and Life Sciences ; Biomedicine ; Correlation ; Dermatology ; Foxp3 protein ; Immunological tolerance ; Immunology ; Immunotherapy ; Leukocytes (mononuclear) ; Lymphocytes T ; Neurology ; Oral administration ; Original Research Paper ; Patients ; Peripheral blood mononuclear cells ; Pharmacology/Toxicology ; Pollinosis ; Rheumatology</subject><ispartof>Inflammation research, 2021-05, Vol.70 (5), p.581-589</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021</rights><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-8297c16333fc706570c6f1979461fa58cb878555b2de62c5394e00909c3334613</citedby><cites>FETCH-LOGICAL-c375t-8297c16333fc706570c6f1979461fa58cb878555b2de62c5394e00909c3334613</cites><orcidid>0000-0002-5225-8375</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00011-021-01460-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00011-021-01460-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33837438$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Terada, Tetsuya</creatorcontrib><creatorcontrib>Matsuda, Masaya</creatorcontrib><creatorcontrib>Inaba, Miki</creatorcontrib><creatorcontrib>Hamaguchi, Junpei</creatorcontrib><creatorcontrib>Takemoto, Naoki</creatorcontrib><creatorcontrib>Kikuoka, Yusuke</creatorcontrib><creatorcontrib>Inaka, Yuko</creatorcontrib><creatorcontrib>Sakae, Harumi</creatorcontrib><creatorcontrib>Hashimoto, Kennosuke</creatorcontrib><creatorcontrib>Shimora, Hayato</creatorcontrib><creatorcontrib>Kitatani, Kazuyuki</creatorcontrib><creatorcontrib>Kawata, Ryo</creatorcontrib><creatorcontrib>Nabe, Takeshi</creatorcontrib><title>Sublingual immunotherapy for 4 years increased the number of Foxp3+ Treg cells, which correlated with clinical effects</title><title>Inflammation research</title><addtitle>Inflamm. Res</addtitle><addtitle>Inflamm Res</addtitle><description>Objective
At least 3 years of sublingual immunotherapy (SLIT) is required to achieve long-term clinical tolerance for allergens. However, immunological changes with more than 3 years of SLIT have not yet been elucidated in detail. The present study investigated whether the numbers of regulatory T (Treg) cells and regulatory B (Breg) cells increased with 4 years of SLIT and if these increases correlated with clinical effects for pollinosis.
Methods
Seven Japanese cedar pollinosis patients received SLIT in 2014 or 2015 and continued treatment until May 2019. In May 2017 and May 2019, peripheral blood mononuclear cells (PBMCs) were collected from the patients, and analyzed by flow cytometer.
Results
(1) The visual analogue scale (VAS) was significantly higher in 2019 than in 2017. (2) The percentages of Foxp3
+
Treg cells, type 1 regulatory T (Tr1) cells, and Breg cells in PBMCs were significantly higher in 2019 than in 2017. (3) The percentage of Foxp3
+
Treg cells in PBMCs positively correlated with VAS, whereas those of Tr1 cells and Breg cells did not.
Conclusions
These results suggest that 4 years of SLIT is needed to achieve sustained increases in Foxp3
+
Treg cells, which are closely associated with the efficacy of SLIT.</description><subject>Allergens</subject><subject>Allergology</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Correlation</subject><subject>Dermatology</subject><subject>Foxp3 protein</subject><subject>Immunological tolerance</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Leukocytes (mononuclear)</subject><subject>Lymphocytes T</subject><subject>Neurology</subject><subject>Oral administration</subject><subject>Original Research Paper</subject><subject>Patients</subject><subject>Peripheral blood mononuclear cells</subject><subject>Pharmacology/Toxicology</subject><subject>Pollinosis</subject><subject>Rheumatology</subject><issn>1023-3830</issn><issn>1420-908X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9kc-KFDEQxoMo7jr6Ah4k4EXQ1sqf7qSPy-KqsODBFbyFdKYy00t3Z0y6GedtfBafzBpnVfDgISSV-tX3FXyMPRXwWgCYNwUAhKhA0hG6gUrdY-dCS6hasF_u0xukqpRVcMYelXJLuJVWPmRnij6NVvac7T8t3dBPm8UPvB_HZUrzFrPfHXhMmesf3w_oc-H9FDL6gmtObT4tY4eZp8iv0redeslvMm54wGEor_h-24ctDylnHPxME_t-pppM-kAmGCOGuTxmD6IfCj65u1fs89Xbm8v31fXHdx8uL66roEw9V1a2JohGKRWDgaY2EJooWtPqRkRf29BZY-u67uQaGxlq1WoEaKENNEKMWrEXJ91dTl8XLLMb-3Lc1E-YluJkLYTUWpPFij3_B71NS55oO6Kk1K0hI6LkiQo5lZIxul3uR58PToA7xuJOsTiKxf2KxR2ln91JL92I6z8jv3MgQJ2AQq1pg_mv939kfwJeGJdC</recordid><startdate>20210501</startdate><enddate>20210501</enddate><creator>Terada, Tetsuya</creator><creator>Matsuda, Masaya</creator><creator>Inaba, Miki</creator><creator>Hamaguchi, Junpei</creator><creator>Takemoto, Naoki</creator><creator>Kikuoka, Yusuke</creator><creator>Inaka, Yuko</creator><creator>Sakae, Harumi</creator><creator>Hashimoto, Kennosuke</creator><creator>Shimora, Hayato</creator><creator>Kitatani, Kazuyuki</creator><creator>Kawata, Ryo</creator><creator>Nabe, Takeshi</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5225-8375</orcidid></search><sort><creationdate>20210501</creationdate><title>Sublingual immunotherapy for 4 years increased the number of Foxp3+ Treg cells, which correlated with clinical effects</title><author>Terada, Tetsuya ; Matsuda, Masaya ; Inaba, Miki ; Hamaguchi, Junpei ; Takemoto, Naoki ; Kikuoka, Yusuke ; Inaka, Yuko ; Sakae, Harumi ; Hashimoto, Kennosuke ; Shimora, Hayato ; Kitatani, Kazuyuki ; Kawata, Ryo ; Nabe, Takeshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-8297c16333fc706570c6f1979461fa58cb878555b2de62c5394e00909c3334613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Allergens</topic><topic>Allergology</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Correlation</topic><topic>Dermatology</topic><topic>Foxp3 protein</topic><topic>Immunological tolerance</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Leukocytes (mononuclear)</topic><topic>Lymphocytes T</topic><topic>Neurology</topic><topic>Oral administration</topic><topic>Original Research Paper</topic><topic>Patients</topic><topic>Peripheral blood mononuclear cells</topic><topic>Pharmacology/Toxicology</topic><topic>Pollinosis</topic><topic>Rheumatology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Terada, Tetsuya</creatorcontrib><creatorcontrib>Matsuda, Masaya</creatorcontrib><creatorcontrib>Inaba, Miki</creatorcontrib><creatorcontrib>Hamaguchi, Junpei</creatorcontrib><creatorcontrib>Takemoto, Naoki</creatorcontrib><creatorcontrib>Kikuoka, Yusuke</creatorcontrib><creatorcontrib>Inaka, Yuko</creatorcontrib><creatorcontrib>Sakae, Harumi</creatorcontrib><creatorcontrib>Hashimoto, Kennosuke</creatorcontrib><creatorcontrib>Shimora, Hayato</creatorcontrib><creatorcontrib>Kitatani, Kazuyuki</creatorcontrib><creatorcontrib>Kawata, Ryo</creatorcontrib><creatorcontrib>Nabe, Takeshi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Inflammation research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Terada, Tetsuya</au><au>Matsuda, Masaya</au><au>Inaba, Miki</au><au>Hamaguchi, Junpei</au><au>Takemoto, Naoki</au><au>Kikuoka, Yusuke</au><au>Inaka, Yuko</au><au>Sakae, Harumi</au><au>Hashimoto, Kennosuke</au><au>Shimora, Hayato</au><au>Kitatani, Kazuyuki</au><au>Kawata, Ryo</au><au>Nabe, Takeshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sublingual immunotherapy for 4 years increased the number of Foxp3+ Treg cells, which correlated with clinical effects</atitle><jtitle>Inflammation research</jtitle><stitle>Inflamm. Res</stitle><addtitle>Inflamm Res</addtitle><date>2021-05-01</date><risdate>2021</risdate><volume>70</volume><issue>5</issue><spage>581</spage><epage>589</epage><pages>581-589</pages><issn>1023-3830</issn><eissn>1420-908X</eissn><abstract>Objective
At least 3 years of sublingual immunotherapy (SLIT) is required to achieve long-term clinical tolerance for allergens. However, immunological changes with more than 3 years of SLIT have not yet been elucidated in detail. The present study investigated whether the numbers of regulatory T (Treg) cells and regulatory B (Breg) cells increased with 4 years of SLIT and if these increases correlated with clinical effects for pollinosis.
Methods
Seven Japanese cedar pollinosis patients received SLIT in 2014 or 2015 and continued treatment until May 2019. In May 2017 and May 2019, peripheral blood mononuclear cells (PBMCs) were collected from the patients, and analyzed by flow cytometer.
Results
(1) The visual analogue scale (VAS) was significantly higher in 2019 than in 2017. (2) The percentages of Foxp3
+
Treg cells, type 1 regulatory T (Tr1) cells, and Breg cells in PBMCs were significantly higher in 2019 than in 2017. (3) The percentage of Foxp3
+
Treg cells in PBMCs positively correlated with VAS, whereas those of Tr1 cells and Breg cells did not.
Conclusions
These results suggest that 4 years of SLIT is needed to achieve sustained increases in Foxp3
+
Treg cells, which are closely associated with the efficacy of SLIT.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>33837438</pmid><doi>10.1007/s00011-021-01460-3</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-5225-8375</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1023-3830 |
| ispartof | Inflammation research, 2021-05, Vol.70 (5), p.581-589 |
| issn | 1023-3830 1420-908X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2511244463 |
| source | SpringerLink |
| subjects | Allergens Allergology Biomedical and Life Sciences Biomedicine Correlation Dermatology Foxp3 protein Immunological tolerance Immunology Immunotherapy Leukocytes (mononuclear) Lymphocytes T Neurology Oral administration Original Research Paper Patients Peripheral blood mononuclear cells Pharmacology/Toxicology Pollinosis Rheumatology |
| title | Sublingual immunotherapy for 4 years increased the number of Foxp3+ Treg cells, which correlated with clinical effects |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T13%3A48%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sublingual%20immunotherapy%20for%204%C2%A0years%20increased%20the%20number%20of%20Foxp3+%20Treg%20cells,%20which%20correlated%20with%20clinical%20effects&rft.jtitle=Inflammation%20research&rft.au=Terada,%20Tetsuya&rft.date=2021-05-01&rft.volume=70&rft.issue=5&rft.spage=581&rft.epage=589&rft.pages=581-589&rft.issn=1023-3830&rft.eissn=1420-908X&rft_id=info:doi/10.1007/s00011-021-01460-3&rft_dat=%3Cproquest_cross%3E2511244463%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2522497555&rft_id=info:pmid/33837438&rfr_iscdi=true |